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Obesity is an increasingly prevalent disease worldwide. While genetic and environmental factors
are known to regulate the development of obesity and associated metabolic diseases, emerging
studies indicate that innate and adaptive immune cell responses in adipose tissue have critical roles
in the regulation of metabolic homeostasis. In the lean state, type 2 cytokine-associated immune
cell responses predominate in white adipose tissue and protect against weight gain and insulin
resistance through direct effects on adipocytes and elicitation of beige adipose. In obesity, these
metabolically beneficial immune pathways becomedysregulated, and adipocytes and other factors
initiate metabolically deleterious type 1 inflammation that impairs glucose metabolism. This review
discusses our current understanding of the functions of different types of adipose tissue and how
immune cells regulate adipocyte function and metabolic homeostasis in the context of health and
disease. We also highlight the potential of targeting immuno-metabolic pathways as a therapeutic
strategy to treat obesity and associated diseases.Introduction
Obesity is in an increasingly prevalent metabolic disease charac-
terized by excess accumulation of adipose tissue. Obesity in-
creases the risk of developing a wide variety of diseases
including but not limited to type 2 diabetes, cardiovascular
diseases, and multiple forms of cancer and has been strongly
associated with increasedmortality (Prospective Studies Collab-
oration, 2009; Flegal et al., 2013; Oliveros and Villamor, 2008;
Pi-Sunyer, 1999; Pontiroli and Morabito, 2011; Reilly and Kelly,
2011; Rodriguez et al., 2001). In the past few decades, the prev-
alence of obesity has risen dramatically in both industrialized and
less industrialized nations across all continents (Kelly et al., 2008;
Ng et al., 2014), and this has been associated with high health-
care expenditures (Withrow and Alter, 2011). For example, in
the U.S. in 2009–2010, obesity afflicted 36% of adults (Flegal
et al., 2012; Ogden et al., 2012, 2014) and accounted for approx-
imately $190 billion in annual healthcare costs, representing
nearly 20% of total national healthcare expenditures that year
(Cawley and Meyerhoefer, 2012; Finkelstein et al., 2009). More
recent statistics indicate that 35% of adults in the U.S. were
obese in 2011–2012 but was as high as 48% in some segments
of the population (Ogden et al., 2014). Therefore obesity is a crit-
ical problem with major health and economic consequences.
Increasing our understanding of the pathways involved in the
development of obesity will be critical for the development of
new intervention strategies to prevent or treat this disease and
its associated co-morbidities.
As in many chronic inflammatory diseases, genetic and envi-
ronmental factors are important for the development of obesity
and associated diseases (Bouchard, 2008; Brestoff and Artis,146 Cell 161, March 26, 2015 ª2015 Elsevier Inc.2013; McCarthy, 2010; Walley et al., 2009). In addition, emerging
studies have implicated various cell types of the immune system
as critical regulators of metabolic homeostasis (Jin et al., 2013;
Lumeng and Saltiel, 2011; Odegaard and Chawla, 2011, 2013b;
Osborn and Olefsky, 2012). Seminal studies connecting the im-
mune system to metabolic dysfunction in obesity indicated that
tumor necrosis factor-a (TNF-a) production was upregulated in
obese mice and that neutralization of TNF-a improved glucose
uptake in murine obesity (Hotamisligil et al., 1993). Subsequent
studies revealed that mice lacking TNF-a were protected from
high-fat-diet-induced insulin resistance (Uysal et al., 1997).
Increased TNF-a production was also observed in human
obesity, and weight loss in humans was associated with
decreased TNF-a levels (Hotamisligil et al., 1995; Kern et al.,
1995). Later, it was discovered that pro-inflammatory macro-
phages accumulate in adipose of obesemice and that these cells
were dominant sources of TNF-a to promote insulin resistance
(Weisberg et al., 2003; Xu et al., 2003). Collectively, these studies
revealed that obesity is associated with chronic low-grade
inflammation and suggested that inflammatory responses can
have detrimental metabolic consequences. It is now appreciated
that in obesity chronic low-grade inflammation occurs in many
organs including but not limited to white adipose tissue (WAT),
brown adipose tissue (BAT), pancreas, liver, brain, muscle, and
intestine (Cildir et al., 2013). Of these, WAT is the most studied
organ in terms of immune-metabolic interactions in obesity.
In WAT, which coordinates metabolism at distant tissues such
as the brain, liver, pancreas, and muscle, there is a diverse set of
immune cells at steady state (Exley et al., 2014; Ibrahim, 2010;
McNelis and Olefsky, 2014; Mraz and Haluzik, 2014). This
Figure 1. White, Beige, and Brown Adipo-
cytes Are Developmentally and Functionally
Distinct Cell Populations
White and beige adipocytes arise from a Myf5
precursor cell population that is bipotent. These
pre-adipocytes give rise to white or beige adipo-
cytes depending on the stimulus and physiologic
setting. White adipocytes are promoted by high-
fat-diet feeding or obesity and by thermoneutrality
(30C in mice). Beige adipocytes are elicited by
b3 adrenergic receptor agonists such as norepi-
nephrine or epinephrine, and are recruited within
WAT in the settings of chronic exercise or
exposure to cold temperatures. Although white
and beige adipocytes emerge from pre-adipo-
cytes via cell differentiation, mature white and
beige adipocytes might undergo a process
called transdifferentiation, in which one cell
type acquires phenotypic characteristics of the
other. There is uncertainty about whether
transdifferentiation occurs. In contrast, brown
adipocytes arise from a Myf5+ precursor cell
population and are present in discrete brown adipose tissue depots. Despite being developmentally distinct cell populations, beige and brown adipocytes are
activated by similar physiologic stimuli, including exercise- and cold temperature-induced hormones and metabolites.network of immune cells appears to be poised to recognize,
integrate, and respond to environmental signals including bacte-
rial products, endogenous lipid species and hormones in
order to regulate metabolism (Odegaard and Chawla, 2013a).
Changes in immune cell composition and function in WAT have
been closely associated with obesity and the regulation of meta-
bolic homeostasis, and disruption of this network of immune
cells can have either detrimental or beneficial effects on
mammalian health (Exley et al., 2014; Lumeng and Saltiel,
2011; Mraz and Haluzik, 2014; Odegaard and Chawla, 2013b;
Osborn and Olefsky, 2012). In addition, recent work has demon-
strated that immune-system-associated transcription factors
including but not limited to nuclear factor-k B (NK-kB), c-Jun
kinase (JNK), and interferon regulatory factor 4 (IRF4) are
key regulators of metabolic homeostasis (Lumeng and Saltiel,
2011; Osborn and Olefsky, 2012). Conversely, metabolite-
sensing receptors such as peroxisome proliferator-activated
receptor (PPAR)-g, farnesoid X receptor (FXR), liver X receptor
(LXR), G protein coupled receptor 120 (GPR120), and carbohy-
drate-responsive element binding protein (ChREBP) among
others have been shown to regulate immune responses (Brestoff
and Artis, 2013; Glass and Saijo, 2010; Hotamisligil and Erbay,
2008; Shoelson et al., 2007; Zelcer and Tontonoz, 2006). There-
fore dissecting the complex interactions between immune
and metabolic systems will provide important insights into the
biology underlying obesity and have implications for under-
standing how current and future therapeutics might influence
metabolism.
The purpose of this review is to describe our current under-
standing of how immune cells in adipose tissue regulate meta-
bolism. First, we will summarize recent advances in understand-
ing the roles of white, beige, and brown adipose tissues in the
regulation of weight gain. Second, we will describe the immune
cell composition of adipose tissue at steady state and discuss
how these immune cell pathways interact and contribute to the
maintenance of metabolic homeostasis. Third, we will discuss
immunologic changes that occur in adipose in the setting of
obesity and highlight how these changes contribute tometabolicdysfunction. Finally, we will discuss potential therapeutic impli-
cations of targeting the immune system to treat obesity and its
associated diseases.
Roles of Adipose Tissues in the Regulation of Obesity
Mammals possess multiple types of adipose tissues including
white, brown, and beige adipose. These tissues are found in
distinct anatomic locations and are comprised of different adipo-
cyte cell types—white, beige, and/or brown—that have unique
developmental and functional properties that are critical for
host metabolism (Figure 1) (Bartelt and Heeren, 2014; Cannon
and Nedergaard, 2004; Harms and Seale, 2013; Ibrahim, 2010;
Peirce et al., 2014; Pfeifer and Hoffmann, 2015; Wu et al.,
2013). This section describes white, brown, and beige adipocyte
cell types and summarizes their roles in regulating weight gain.
White Adipocytes
WAT is distributed throughout the mammalian body in subcu-
taneous depots and in association with organs, where it has
important roles in insulation and physical protection of the
viscera, and is comprised predominantly of white adipocytes
(Peirce et al., 2014; Pfeifer and Hoffmann, 2015). These special-
ized cell types arise from a Myf5 pre-adipocyte lineage and
store large amounts of triglycerides in a single large lipid droplet
(Pfeifer and Hoffmann, 2015; Sanchez-Gurmaches and Guertin,
2014). In addition to their ability to store triglycerides, white adi-
pocytes respond to hormonal signals to induce lipolysis and
release free fatty acids (FFA) into the circulation for oxidation
or storage by other cell types (Arner et al., 2011; Bartness
et al., 2010). Therefore white adipocytes are critical for regulating
both fat storage and release. Beyond this function, white adipo-
cytes produce various adipocyte-specific hormones (also known
as adipokines) including but not limited to leptin, resistin, retinol
binding protein 4 (RBP4), fibroblast grown factor 21 (FGF21), and
adiponectin that regulate metabolic homeostasis by acting on
distant organs such as the brain, kidney, liver, pancreas, and
skeletal muscle (Allison and Myers, 2014; Itoh, 2014; Kadowaki
et al., 2006; Kershaw and Flier, 2004; Kotnik et al., 2011; Lazar,
2007; Ouchi et al., 2011).Cell 161, March 26, 2015 ª2015 Elsevier Inc. 147
In the context of obesity, mature white adipocytes undergo
proliferation and become hypertrophic through accumulation of
triglycerides to increase the number and size of the adipocyte
pool in WAT (Foster and Bartness, 2006; Hausman et al., 2001;
Kubota et al., 1999; Spalding et al., 2008). As WAT expands, ad-
ipocytes increase production of leptin to suppress food intake
and therefore limit the rate of triglyceride accumulation and
adipocyte expansion (Allison and Myers, 2014). In obesity, this
food intake-suppressive effect of upregulated leptin production
is blunted by the development of resistance to leptin action
(Park and Ahima, 2015). Leptin also has pro-inflammatory effects
by eliciting type 1 effector cytokine production by immune cells
(Attie and Scherer, 2009; Gregor and Hotamisligil, 2011; Mraz
and Haluzik, 2014; Ouchi et al., 2011). In addition to leptin, the
adipokines RBP4 and resistin are increased in obesity and pro-
mote insulin resistance in mice (Kotnik et al., 2011; Lazar, 2007;
Moraes-Vieira et al., 2014; Norseen et al., 2012; Steppan et al.,
2001; Yang et al., 2005). Upregulation of RBP4 expression has
been linked to inappropriate sensing of low glucose levels by
adipocytes (Yang et al., 2005), whereas resistin production is
increased due to elevated levels of insulin and TNF-a among
other factors (Lazar, 2007; Song et al., 2002). Both of these fac-
tors appear to promote insulin resistance in mice, at least in
part, through elicitation of type 1 immune responses in WAT
(Jung and Choi, 2014; Ouchi et al., 2011). Thus, leptin, resistin,
and RBP4 are pro-inflammatory factors that are increased in
obesity and that stimulate type 1 immunity in WAT.
In contrast, adiponectin has anti-inflammatory and insulin-
sensitizing effects (Gregor and Hotamisligil, 2011; Kadowaki
et al., 2006; Lumeng and Saltiel, 2011). Adiponectin production
by white adipocytes is decreased in the context of obesity
(Ouchi et al., 2011), and loss of this anti-inflammatory signal
may be one factor that contributes to the development of
inflammation in WAT in obesity. Other adipokines are also
emerging as potential anti-inflammatory factors. In particular,
recent work suggests that FGF21 might have immunosuppres-
sive effects through inhibition of the transcription factor nuclear
factor-kB (NF-kB) (Yu et al., 2015), a master regulator of inflam-
matory gene expression. Additional research is needed to deter-
mine whether FGF21 regulates inflammation in obesity and
whether the immune system regulates expression of FGF21.
Other adipokines such as fatty acid binding protein 4 (also
known as adipocyte protein 2) and neuregulin 4 (NRG4) that
have important roles in regulating metabolism have also been
associated with inflammatory markers (Cao et al., 2013; Terra
et al., 2011; Wang et al., 2014). Future research will be needed
to determine whether these adipokines are direct pro- or anti-
inflammatory mediators in WAT. Therefore, white adipocytes
appear to link metabolic status of mammals to immune re-
sponses in WAT.
Brown Adipocytes
Although brown adipocytes can also produce adipokines, these
cells differ from white adipocytes developmentally and function-
ally and in their anatomic distribution. In mice, brown adipocytes
arise from aMyf5+ lineage and are developmentally more closely
related to skeletal muscle cells than to white adipocytes (Kaji-
mura et al., 2009; Seale et al., 2008). The primary function of
brown adipocytes in both mice and humans is to convert chem-148 Cell 161, March 26, 2015 ª2015 Elsevier Inc.ical energy into heat via uncoupling protein 1 (UCP1) (Cannon
and Nedergaard, 2004). UCP1 is a long chain fatty acid/proton
symporter that dissipates the mitochondrial electrochemical
gradient, thereby uncoupling energy substrate oxidation from
ATP synthesis and resulting in the generation of heat (Fedorenko
et al., 2012; Matthias et al., 2000). This process is critical for
maintaining core body temperature and in the regulation of
weight gain by increasing whole-body energy expenditure. In
the latter case, for example, mice that lack UCP1 develop
obesity when housed at thermoneutrality (30C) as compared
to UCP1-sufficient controls (Feldmann et al., 2009). Although
global deletion of UCP1 impairs thermogenesis in both brown
and beige adipocytes (see below), brown adipose tissue (BAT)
is believed to be an important regulator of metabolic rate and
obesity susceptibility in mice.
Brown adipocytes are found in discrete BAT depots. In mice,
the largest BAT depot is present in the interscapular space,
and smaller depots are present in the axilla and along the cervical
column (Bartelt and Heeren, 2014). In humans, brown adipo-
cytes are abundant in newborns including in the interscapular
space (Hondares et al., 2014), whereas in lean adult humans
brown adipocytes are reported to be present in the supraclavic-
ular space of the neck and adjacent to the cervical column and
heart (van Marken Lichtenbelt et al., 2009; Virtanen et al.,
2009). Subsequent studies have determined that supraclavicular
neck BAT in healthy adults exhibits a gene expression profile and
has morphologic characteristics consistent with those of beige
adipocytes (Lee et al., 2014a; Sharp et al., 2012; Wu et al., 2012).
Beige Adipocytes
Like brown adipocytes, beige adipocytes (also known as brown-
like or brite adipocytes) express high levels of UCP1 and store
triglyceride in one ormore lipid droplets, giving rise to a pauciloc-
ular or multilocular cell morphology. Although beige and brown
adipocytes have similar UCP1-dependent functional character-
istics, these cell types differ from each other developmentally
and anatomically. Brown adipocytes arise from a Myf5+ precur-
sor and are developmentally related to skeletal muscle cells (Ka-
jimura et al., 2009; Seale et al., 2008), whereas beige adipocytes
arise from Myf5 precursors within WAT and are developmen-
tally related to smooth muscle cells (Long et al., 2014) and/or
white adipocytes (Sanchez-Gurmaches and Guertin, 2014).
Beige adipocytes may arise from multiple developmental path-
ways, including differentiation from committed beige pre-adipo-
cytes as well as white-to-beige transdifferentiation in which
mature white adipocytes are converted into beige adipocytes
(Figure 1) (Barbatelli et al., 2010; Harms and Seale, 2013; Moisan
et al., 2015; Sanchez-Gurmaches andGuertin, 2014;Wang et al.,
2013b; Wu et al., 2012). While differentiation is a well-accepted
developmental pathway for beige adipocytes, white-to-beige
transdifferentiation is a controversial topic, and further research
is needed to determinewhether this process contributes to beige
adipogenesis in different physiologic contexts or in response to
different stimuli. In mice, beige adipocytes are enriched in sub-
cutaneousWAT compared to visceral fat. However, beige adipo-
cytes are elicited in both types of WAT (Qiu et al., 2014), and
future studies will be required to determine whether beige adipo-
cytes in subcutaneous and visceral fat differ from each other
developmentally and/or functionally.
Figure 2. Healthy White Adipose Tissue Is
Enriched in Type 2 Cytokine-Associated
Immune Cells
In the lean state, adipocytes and endothelial cells in
white adipose tissue (WAT) constitutively produce
interleukin (IL)-33 that can act on Group 2 innate
lymphoid cells (ILC2s) to induce production of IL-5
and IL-13 that sustain eosinophil and alternatively
activated macrophage (AAMac) responses, res-
pectively, in WAT. In addition, eosinophils produce
IL-4 that is necessary to maintain AAMac re-
sponses in WAT. AAMacs have multiple functions
to maintain metabolic homeostasis, including
storing large amounts of iron, leading to seques-
tration of this pro-oxidative metal cation from adi-
pocytes to prevent lipid peroxidation, oxidative
damage to proteins andmitochondrial dysfunction.
In addition, AAMacs produce norepinephrine (NE)
that acts on both white and beige adipocytes via
the b3 adrenergic receptor to stimulate lipolysis and
elicit beige adipocytes that increasemetabolic rate. ILC2s can also promote beiging through production of methionine-enkephalin (MetEnk) peptides. In addition,
adipocytes present lipid antigen to invariant natural killer T (iNKT) cells to elicit a unique tissue-specific anti-inflammatory phenotype characterized by increased
production of IL-4 and IL-13, which may act on AAMacs, and IL-10. Lipids from adipocytes are also believed to promote regulatory T cell (Treg) responses in WAT
to induce production of IL-10. iNKT cells are critical sources of IL-2 and are necessary to sustain Tregs in WAT. IL-10 production by iNKT cells, Tregs and other cell
types promote insulin action in white adipocytes to facilitate maintenance of an insulin-sensitive state. Together, these pathways contribute to metabolically
healthy WAT.Beige adipocytes are elicited in response to environmental
stimuli including exposure to cold environmental temperatures
or in response to exercise, and these cells are activated or
induced to differentiate in response to a range of small molecules
and hormones. Factors that stimulate beige adipocyte develop-
ment or activation include norepinephrine (NE) (Qiu et al., 2014;
Rao et al., 2014), adenosine (Gnad et al., 2014), lactate (Carrie`re
et al., 2014), b-aminoisobutyric acid (BAIBA) (Roberts et al.,
2014), prostaglandin E2 (PGE2) (Madsen et al., 2010), parathyroid
hormone-related protein (PTHrp) (Fisher et al., 2012), bone
morphogenetic protein 4 (BMP4) (Qian et al., 2013), BMP7
(Schulz et al., 2011), fibroblast growth factor 21 (FGF21) (Fisher
et al., 2012), irisin (Wu et al., 2012), and meteorin-like (Rao
et al., 2014). Although many factors are known to promote beige
adipocyte differentiation or function, it remains unknownwhether
these factors act on different subsets of beige adipocytes or
whether they elicit developmentally or functionally distinct sub-
sets of beige adipocytes. In addition, it is unclear to what extent
these factors coordinately regulate beige adipocyte function.
Nonetheless, recent studies indicate that selective deletion of
beige but not brown adipocytes results in impaired glucose ho-
meostasis and increased susceptibility toweight gain in response
to high fat diet (HFD) feeding (Cohen et al., 2014). Conversely,
mice with increased beige adipocytes exhibit increased meta-
bolic rate and decreased obesity (Wang et al., 2013a). Consistent
with this finding, 129Sv mice, which are resistant to diet-induced
obesity exhibit increased beiging of WAT compared to C57BL/6
mice, which are susceptible to diet-induced obesity (Shabalina
et al., 2013). Inhibition of beige adipocytes by supplementing
HFD chow with indomethacin resulted in increased weight gain
following HFD feeding in 129Sv mice (Madsen et al., 2010).
Collectively, these data indicate that impaired beiging is associ-
ated with increased weight gain and suggest that elicitation of
beige adipocytes can combat obesity in mice.
Recent studies support the relevance of these findings in
humans. In the context of human obesity, the incidence ofbrown/beige adipose tissue (Sharp et al., 2012) is significantly
decreased in obese patients compared to lean patients (Saito
et al., 2009). In addition, UCP1 expression was found to be
higher in cultured beige adipocytes from lean patients compared
to obese patients, suggesting that beige adipocyte differentia-
tion or activation is impaired in human obesity (Carey et al.,
2014). Consistent with this, ephedrine-induced activation of
brown/beige adipose tissue is impaired in human obesity (Carey
et al., 2013). While the role of brown/beige adipocytes in the
regulation of energy expenditure in humans is unclear, these
studies suggest that obesity is associated with loss of beige fat
function and raise the possibility that defective beige fat may
have deleterious metabolic effects including increased suscepti-
bility to weight gain.
Immune Cell Composition and Function in Lean White
Adipose Tissue
White adipose is a heterogeneous tissue comprised of multiple
cell types including a diverse array of immune cells. In the
steady state, these immune cells tend to be associated with
the type 2 immune axis and include alternatively activated mac-
rophages (AAMacs), eosinophils, Group 2 innate lymphoid cells
(ILC2s), invariant natural killer T (iNKT) cells, T helper type 2
(Th2) cells, regulatory T (Treg) cells, and other immune cell pop-
ulations that communicate with each other and participate in
cross-talk with adipocytes. As discussed below, the interface
between immune cells and adipocytes contributes to the regu-
lation of lipid storage, glucose utilization, redox balance, and
energy expenditure (Figure 2). However, in the context of
obesity, type 2 immune cells in WAT become dysregulated
and, in some cases, acquire a pro-inflammatory phenotype
that exacerbates adipose tissue inflammation with deleterious
effects on metabolism. In this section, we discuss emerging
concepts in the composition and function of immune cells in
WAT at steady state and how these cells contribute to protec-
tion from diet-induced obesity.Cell 161, March 26, 2015 ª2015 Elsevier Inc. 149
Figure 3. Immunologic Mechanisms That Regulate Beiging
In the context of chronic exposure to cold environmental temperatures or
chronic exercise, WAT and muscle produce the adipokine/myokine meteorin-
like. This hormone and other factors such as IL-5 promote eosinophil accu-
mulation inWAT. Eosinophils produce IL-4 that sustains alternatively activated
macrophages (AAMacs). IL-4 and perhaps IL-13 act on AAMacs to stimulate
norepinephrine (NE) production. NE acts to stimulate beiging via differentiation
and/or transdifferentiation pathways and to activate existing beige adipocytes,
resulting in mitochondrial biogenesis, uncoupling protein 1 (UCP1) upregula-
tion, and UCP1-dependent increases in energy expenditure. In addition, WAT
produces the cytokine IL-33 that is critical for maintaining ILC2 responses in
WAT. IL-33 stimulates ILC2s to produce IL-5 and IL-13 that sustain the
eosinophil/AAMac pathways that can contribute to beiging. In addition, IL-13
can act on pre-adipocytes to promote their proliferation and induce differen-
tiation to beige adipocytes. Further, IL-33 stimulates ILC2s to produce
methionine-enkephalin (MetEnk) peptides that can directly promote beiging.
Therefore AAMacs and ILC2s both contribute to beiging through production of
distinct effector molecules.The IL-4/Alternatively Activated Macrophage Pathway
AAMacs are IL-4- and IL-13-dependent cells that require signal
transducer and activator of transcription 6 (STAT6) to maintain
an alternative activation state that is distinct from the classical
activation state induced by interferon-g (IFNg) (Gordon andMar-
tinez, 2010; Hill et al., 2014; Martinez et al., 2009; Odegaard and
Chawla, 2011; Olefsky and Glass, 2010). AAMacs are critical for
protective immunity against helminth pathogens and are associ-
ated with pathologic allergic inflammation in the lung (Gordon150 Cell 161, March 26, 2015 ª2015 Elsevier Inc.and Martinez, 2010; Martinez et al., 2009). Recent studies have
also implicated AAMacs in the regulation of metabolic homeo-
stasis (Hill et al., 2014; Odegaard and Chawla, 2011; Olefsky
and Glass, 2010). Early studies linking AAMacs to metabolism
demonstrated that macrophage-specific deletion of Peroxisome
proliferator-associated receptor (PPAR)-g results in decreased
AAMacs in WAT in association with increased weight gain,
elevated fat accumulation, impaired glucose uptake and insulin
resistance following HFD feeding (Odegaard et al., 2007). In
addition, deletion of PPAR-d in leukocytes also impaired AAMac
responses and was associated with increased adiposity and in-
sulin resistance (Odegaard et al., 2008). These loss-of-function
studies are complemented by gain-of-function approaches indi-
cating that administration of exogenous IL-4 to mice to boost
AAMac responses protected mice from HFD-induced obesity
and insulin resistance (Chang et al., 2012; Ricardo-Gonzalez
et al., 2010). Together, these studies identified a critical role for
the IL-4/AAMac axis in the regulation of metabolic homeostasis.
Emerging work has revealed that AAMacs employ a diverse
functional repertoire to regulate metabolism. For example, a
subset of AAMacs in WAT can express genes involved in iron
handling and has the capacity to store large amounts of iron in
lean mice (Orr et al., 2014). The capacity of these specialized
AAMacs to store iron is diminished in the setting of obesity, lead-
ing to abnormal accumulation of iron in adipocytes (Orr et al.,
2014) that may lead to iron-initiated production of highly toxic
lipid aldehydes that damage cellular proteins, impair adipocyte
insulin sensitivity, and lead to mitochondrial dysfunction (Curtis
et al., 2010; Curtis et al., 2012). Therefore it appears that special-
ized iron-storing AAMacs have an essential role in regulating iron
homeostasis in WAT to maintain optimal glucose metabolism
and mitochondrial function at steady state, and dysregulation
of these cells in obesity may have deleterious effects on glucose
and energy homeostasis. Consistent with this, treatment of
obese mice with the iron chelator deferoxamine is associated
with improved glucose tolerance, decreased body weight, lower
fat mass, and less inflammation in fat compared to vehicle-
treated obese controls (Tajima et al., 2012).
In addition, AAMacs from adipose are capable of producing
catecholamines such as norepinephrine (NE) that act on adipo-
cytes via the b3 adrenergic receptor (b3AR) to stimulate lipolysis,
activate mitochondrial biogenesis and upregulate expression of
UCP1 (Figures 2 and 3) (Liu et al., 2014; Nguyen et al., 2011;
Qiu et al., 2014; Rao et al., 2014). AAMac-derived catecholamine
production was described in the setting of brown adipocyte
activation (Nguyen et al., 2011). Mice that lack IL-4 and IL-13
(Il4/13/); the shared receptor for these cytokines, IL-4Ra
(Il4ra/); or STAT6, a transcription factor downstream of IL-
4Ra signaling (Stat6/), had defective AAMac responses (Marti-
nez et al., 2009) and exhibited decreased UCP1 expression in
BAT (Nguyen et al., 2011). This defect in UCP1 expression in
BAT was associated with impaired maintenance of core body
temperature following acute exposure to cold environmental
temperatures over a 6 hr period compared to wild-type controls
(Nguyen et al., 2011). These findings suggested that IL-4/IL-
4Ra-dependent activation of AAMacs stimulated production
of NE that was necessary for brown adipocyte activation in
the setting of short-term cold exposure. However, subsequent
studies indicated that IL-4/IL-4Ra-dependent AAMacs were
dispensable for brown adipocyte activation in the setting of
more prolonged cold exposure over 72 hr (Qiu et al., 2014). This
suggests that there may be time-dependent factors that influ-
ence whether the IL-4/AAMac/NE pathway activates brown adi-
pocytes, a topic that should be investigated further.
The IL-4/AAMac/NE pathway is also critical for activating
beige adipocytes in WAT (Figure 3) (Qiu et al., 2014; Rao
et al., 2014). Mice lacking IL-4/IL-13, IL-4Ra, or STAT6 failed
to undergo optimal beiging of WAT and had decreased meta-
bolic rate compared to wild-type controls after 72 hr of expo-
sure to cold environmental temperatures (Qiu et al., 2014; Rao
et al., 2014). This phenotype appears to be mediated by macro-
phage-intrinsic production of NE, as mice that lack the rate-
limiting step of catecholamine synthesis, tyrosine hydroxylase
(TH), in LysM-Cre-expressing cells such as macrophages
exhibit impaired beige adipose development and exhibit a
10%–15% decrease in whole-body oxygen consumption in
the setting of chronic exposure to mild (room temperature) or
severe (5C) cold environmental temperatures (Qiu et al.,
2014). This defect in metabolic rate suggests that AAMac-
derived catecholamines might also be important for limiting
weight gain. Consistent with this, mice that lack Receptor inter-
acting protein 140 (RIP140), a transcriptional co-regulator that
regulates metabolism in various tissues and that suppresses
mitochondrial uncoupling (Rosell et al., 2011), had increased
AAMac responses in WAT and increased beiging that was
associated with protection from diet-induced obesity (Liu
et al., 2014). In addition, treatment of mice with exogenous
IL-4 elicits beiging and increases oxygen consumption levels
in an UCP1-dependent manner, effects that are associated
with decreased severity of diet-induced obesity (Chang et al.,
2012; Qiu et al., 2014; Ricardo-Gonzalez et al., 2010). In addi-
tion to its effects on AAMacs, IL-4 can act directly on pre-
adipocytes to promote beige adipocyte development (Lee
et al., 2015). Together, these data suggest that IL-4 in WAT is
critical for beiging and regulation of metabolic rate through
UCP1-dependent thermogenesis.
Sources of IL-4 in WAT: Eosinophils and Invariant
Natural Killer T Cells
The appreciation of AAMacs as critical regulators of metabolic
homeostasis sparked interest in determining the cellular sources
of IL-4 in WAT. Using the 4get mouse, a reporter strain that
identifies IL-4-competent cells, eosinophils were identified as
an abundant immune cell population in WAT and an important
source of IL-4 in this compartment at steady state (Wu et al.,
2011). Eosinophils are granulocytes that are developmentally
dependent on the cytokine IL-5 and the transcription factor
GATA-binding protein 1 (GATA-1), and these cells contribute to
type 2 immune responses by producing a variety of effector mol-
ecules including IL-4 (Rosenberg et al., 2013; Rothenberg and
Hogan, 2006). Eosinophils are decreased in WAT of HFD-fed
and genetically obese ob/ob mice (Wu et al., 2011). DDblGata1
mutants or IL-5-deficient mice, both of which lack eosinophils
(Rosenberg et al., 2013; Rothenberg and Hogan, 2006), develop
more severe obesity and insulin resistance than wild-type con-
trols in association with dysregulated AAMac responses (Wu
et al., 2011). Further, mice with elevated numbers of eosinophilsin WAT due to constitutive overexpression of IL-5 or infection
with helminth pathogens were protected from diet-induced
obesity and insulin resistance (Wu et al., 2011; Yang et al.,
2013). Eosinophils are also recruited to WAT in the setting of
chronic exposure to cold environmental temperatures, and
eosinophil-deficient DDblGata1 mice exhibit defective beiging
ofWAT (Qiu et al., 2014; Rao et al., 2014). These beneficial meta-
bolic effects of eosinophils appear to be mediated by IL-4-
dependent AAMac responses in WAT (Wu et al., 2011; Qiu
et al., 2014); however, whether eosinophils have other functions
in WAT remains unknown.
In addition to eosinophils, iNKT cells that express lipid antigen-
specific T cell receptor variants appear to be an important source
of IL-4 inWAT (Hams et al., 2013; Lynch et al., 2012). iNKT cells in
WAT produce more IL-4 and IL-10 and less IFN-g than do iNKT
cells in the liver and spleen (Lynch et al., 2012), suggesting that
iNKT cells inWAT are in an ‘‘alternative activation’’ state. Consis-
tent with this, recent work has shown that mammals produce
endogenous lipid antigens such as a-galactosylceramides
(aGalCer) that promote production of type 2 cytokines by iNKT
cells (Kain et al., 2014; Lynch et al., 2012), and that adipocytes
can present lipid antigens to iNKT cells via CD1d (Huh et al.,
2013; Rakhshandehroo et al., 2014). iNKT cells are decreased
in murine and human obesity, and surgical or dietary treatment
of obesity restores iNKT cells inWAT (Lynch et al., 2012). Genetic
studies in mice provide further support for the hypothesis that
iNKT cells play a critical role in maintenance of body weight
and metabolism. Ja18-deficient mice, which lack iNKT cells,
exhibit increased body weight and adiposity when fed a HFD
compared to wild-type controls, and CD1d-deficient mice,
which cannot present lipid antigen to iNKT cells, develop spon-
taneous obesity on a low-fat diet (Lynch et al., 2012). In addition,
mice lacking iNKT cells had more severe glucose intolerance
and increased pro-inflammatory macrophages in WAT (Lynch
et al., 2012), suggesting that iNKT cells are essential for limiting
inflammatory responses in the setting of obesity. Adoptive trans-
fer of iNKT cells induced weight loss and decreased adipocyte
size while improving insulin resistance in HFD-fed mice (Hams
et al., 2013; Lynch et al., 2012), and treatment of HFD mice
with aGalCer recapitulated these effects in an iNKT-dependent
manner by increasing IL-4 and IL-10 production by iNKT cells
(Lynch et al., 2012). Therefore, eosinophils and iNKT cells may
be important sources of IL-4 or other factors that support AAMac
function or that directly regulate metabolic homeostasis to limit
obesity and insulin resistance.
The IL-33/Group 2 Innate Lymphoid Cell Pathway
ILC2s are recently described immune cells (Moro et al., 2010;
Price et al., 2010; Neill et al., 2010) that control eosinophil and
AAMac responses (Molofsky et al., 2013; Nussbaum et al.,
2013). ILC2s are members of a broader family of ILCs that
comprise T-bet-dependent Group 1 ILCs that produce IFN-g;
GATA-3-dependent ILC2s that produce IL4, IL-5, IL-9, IL-13,
and amphiregulin; and RORgt-dependent Group 3 ILCs that pro-
duce IL-17A and IL-22 (Kim, 2015; Monticelli et al., 2012; Son-
nenberg et al., 2013; Spits et al., 2013; Spits and Cupedo,
2012). At barrier surfaces such as the gut, lung, and skin,
ILC2s respond to epithelial cell-derived cytokines IL-33, IL-25
and thymic stromal lymphopoietin (TSLP) to initiate type 2Cell 161, March 26, 2015 ª2015 Elsevier Inc. 151
immune responses that protect against helminth infection or that
promote pathologic allergic inflammation (Kim, 2015; Monticelli
et al., 2012; Sonnenberg et al., 2013; Spits et al., 2013; Spits
and Cupedo, 2012). ILC2s were recently shown to be present
in murine WAT, where these cells constitutively produce the
effector cytokines IL-5 and IL-13 to maintain eosinophil and
AAMac responses, respectively, in WAT (Molofsky et al., 2013).
Strikingly, eosinophil-deficient mice exhibit decreased energy
expenditure and increased obesity compared to eosinophil-suf-
ficient controls (Molofsky et al., 2013; Wu et al., 2011). Recent
studies showed that antibody-mediated depletion of ILC2s is
associated with increased weight gain and more severe insulin
resistance inmice fed a HFD (Hams et al., 2013), and transferring
IL-25-elicited ILC2swas sufficient to promote weight loss in diet-
induced obesemice (Hams et al., 2013). These data suggest that
ILC2s negatively regulate the development of obesity.
Although ILC2s can regulate metabolic homeostasis through
their effects on eosinophils and AAMacs, they also have direct
effects on metabolism through production of IL-13 and enkeph-
alin peptides (Brestoff et al., 2015; Lee et al., 2015). In the
context of exposure to cold environmental temperatures,
ILC2-derived IL-13 promotes pre-adipocyte proliferation and
differentiation into beige adipocytes in an IL-4Ra-dependent
manner (Lee et al., 2015). The ILC2/IL-13/beiging pathway
may also be related to young age-associated increases in
beiging that may be critical for maintaining core body tempera-
ture during mammalian development (Lee et al., 2015). How-
ever, whether ILC2-derived IL-13 regulates obesity remains
unknown. In this disease context a distinct ILC2-dependent
pathway can promote beiging independently of eosinophils
or IL-4Ra (Brestoff et al., 2015). Specifically, ILC2s produce
methionine-enkephalin (MetEnk) peptides in response to IL-33
stimulation, and MetEnk can act directly on adipocytes from
WAT to upregulate Ucp1 expression levels in vitro and drive
the formation of functional beige adipose tissue in vivo (Brestoff
et al., 2015). MetEnk was previously shown to stimulate lipolysis
in adipocytes (Nencini and Paroli, 1981), a process that is
critical for beige adipocyte responses and UCP1 function
(Fedorenko et al., 2012; Harms and Seale, 2013; Rosen and
Spiegelman, 2014; Wu et al., 2013). Therefore, ILC2s directly
contribute to beiging under various physiologic settings by pro-
ducing IL-13 and MetEnk.
It is possible that ILC2-derived IL-13 andMetEnk, coupledwith
AAMac-derived NE, cooperatively support optimal beiging to
regulatemetabolic homeostasis. Consistentwith this hypothesis,
previous studies have suggested that NE and MetEnk signaling
pathways might interact to cooperatively stimulate lipolysis
in adipocytes (Nencini and Paroli, 1981). Another possibility is
that IL-13, MetEnk and NE elicit distinct populations of beige ad-
ipocytes involved in the regulation of metabolic homeostasis in
different physiologic contexts or following different environ-
mental stressors. Future studies focused on IL-13, MetEnk, and
NE interactions in adipocytes are warranted to better understand
the mechanisms by which ILC2s, eosinophils, and AAMacs
contribute to the regulation of beiging and metabolic rate.
ILC2-mediated regulation of metabolic processes may be
dysregulated in the context of obesity. The cytokine IL-33 is crit-
ical for stimulating proliferation and activation of ILC2s (Kim152 Cell 161, March 26, 2015 ª2015 Elsevier Inc.et al., 2014; Molofsky et al., 2013; Monticelli et al., 2011; Moro
et al., 2010; Neill et al., 2010; Price et al., 2010) and is expressed
at higher levels in WAT of obese mice and humans compared to
non-obese controls (Zeyda et al., 2013). However, ILC2s are
decreased in murine and human obesity (Brestoff et al., 2015;
Molofsky et al., 2013), suggesting that in the obese state ILC2s
may be hypo-responsive to IL-33 or have altered cell death, pro-
liferation, or migration. IL-33 was recently shown to be critical
for protecting mice from obesity (Brestoff et al., 2015; Miller
et al., 2010). Mice lacking IL-33 or the IL-33R exhibit increased
obesity and exacerbated impairments in glucose homeostasis,
and treatment of obese mice with recombinant IL-33 limited
adiposity and improved glucose metabolism in association
with enhanced ILC2 and AAMac responses in WAT (Brestoff
et al., 2015; Miller et al., 2010). This suggests that targeting the
IL-33/ILC2 axis therapeutically could have beneficial metabolic
effects that limit obesity and/or associated diseases such as
type 2 diabetes.
CD4+ T Helper Cells and Regulatory T Cells
In addition to regulating the ILC2/eosinophil/AAMac pathway, IL-
33also actsonadaptive immunecells suchasTh2cells (Molofsky
et al., 2013) and Tregs (Schiering et al., 2014). Although Th2 cells
are relatively rare inWAT (Molofsky et al., 2013) and remainpoorly
understood in the context of obesity, Tregs in WAT have been
shown to be uniquemembers of the Treg pool exhibiting elevated
expression of PPAR-g, Foxp3, and IL-10 compared to Tregs in
other tissues (Cipolletta et al., 2012; Deiuliis et al., 2011; Feuerer
et al., 2009). Tregs inWAT contribute to themaintenance of insulin
sensitivity inWAT by limiting inflammation and producing insulin-
sensitizing factors such as IL-10 (Cipolletta et al., 2012; Feuerer
et al., 2009; Ilan et al., 2010). For example, IL-10 suppresses
monocyte chemotactic protein-1 (MCP-1) expression by adipo-
cytes to limit inflammatory macrophage infiltration of WAT and
inhibits the ability of TNF-a to downregulate glucose transporter
4 (GLUT-4) expression and impair insulin action in adipocytes
(Lumeng et al., 2007). In obesity, Tregs are decreased in both
mice and humans (Cipolletta et al., 2012; Feuerer et al., 2009;
Wagner et al., 2013), which may be due to aberrant iNKT cell
responses in obese WAT (Lynch et al., 2015). iNKT cells in WAT
produce IL-2 to sustain Tregs and are an additional source of IL-
10 (Lynch et al., 2015; Lynch et al., 2012). Interestingly, recent
studies indicate that the anti-diabetic class of drugs known as
thiazoladinediones (TZD),whicharePPAR-gagonists, ameliorate
insulin resistance in obese mice in part via their effects on Tregs
(Cipolletta et al., 2012). Therefore promoting Treg responses
may be a useful strategy to treat or prevent type 2 diabetes.
Immune Cell Responses in White Adipose Tissue in
Obesity
In obesity, WAT undergoes metabolic and inflammatory
changes. As white adipocytes accumulate triglycerides and
become hypertrophic, the vasculature in WAT becomes rarified
leading to hypoxia and oxidative stress (Curtis et al., 2010; Pa-
sarica et al., 2009). In addition, increased oxygen consumption
by adipocytes undergoing hypertrophy results in relative local
hypoxia that triggers hypoxia-inducible factor 1 a (HIF-1a) acti-
vation (Lee et al., 2014b). These changes are associated with
increased adipocyte cell death and elevated production of
Figure 4. Obese White Adipose Tissue Is
Characterized by Type 1 Cytokine-Associ-
ated Immune Responses
In obeseWAT, adipocyte hypertrophy is associated
with hypoxia and adipocyte cell death. Dead and
neighboring adipocytes produce pro-inflammatory
signals such as Monocyte chemotractant protein 1
(MCP1), C-X-C motif chemokine 12 (CXCL12),
retinol binding protein 4 (RBP4) and resistin that
are associated with the recruitment of classically
activated macrophages (MP) into WAT and MP
activation. MP accumulation in WAT is also medi-
ated by pro-inflammatory iNKT cells that exhibit
impaired production of IL-10 and upregulated
production of tumor necrosis factor-a (TNF-a), and
by CD8+ cytotoxic T cells that produce interferon
(IFN)-g. These factors also promote MP activation
and upregulate major histocompatibility complex
class II (MHC II) on MP and adipocytes. MHC II-
mediated antigen presentation by MP and adipo-
cytes stimulates polarization ofCD4+ T cells toward
a T helper type 1 (Th1) phenotype. Supporting this
process are TNF-a, IFN-g, IL-1b and IL-6 collec-
tively producedbyMPcells, dysregulatedAAMacs,
iNKT cells and CD8+ T cells. In addition, leptin is
upregulated in obese WAT, and this factor also
promotes Th1 cell polarization. MP cells, CD8+ T cells and Th1 cells collectively interact to form crown-like structures (CLS) to facilitate phagocytosis of dead
adipocytes (grey cell in center of CLS). This process further promotes antigen presentation and type 1 immune responses, establishing a vicious cycle. Type 1
cytokines such as TNF-a and IFN-g act directly on adipocytes to impair insulin action, leading to insulin resistance. Dysregulated AAMacs also produce type 1
cytokines in the setting of obesity to contribute to insulin resistance. AAMacs also lose their capacity to store iron, resulting in redistribution of iron to adipocytes.
This results in iron-initiated lipid peroxidation that causes reactive oxygen species (ROS) production, insulin resistance, andmitochondrial dysfunction. In addition,
AAMacs in obeseWATpromote collagen deposition inWATand fibrosis, leading ultimately to exacerbated hypoxia and inflammation andpotentiation of the type 1
immune response. These processes occur in the setting of decreased abundance of regulatory T cells (Treg), Group 2 innate lymphoid cells (ILC2), and eosinophils
(Eos) that promote insulin sensitivity and metabolic homeostasis in WAT in the steady state. Mito, mitochondrion.adipocyte-derived inflammatory mediators, including the adipo-
kines leptin, resistin and RBP4 (Attie and Scherer, 2009; Green-
berg and Obin, 2006; Lazar, 2007; McNelis and Olefsky, 2014;
Osborn and Olefsky, 2012; Ouchi et al., 2011). As discussed
below, these and other pro-inflammatory factors initiate a type
1 immune response in obese WAT that is characterized by
increased accumulation of CD4+ T helper type 1 (Th1) cells, cyto-
toxic CD8+ T cells, and pro-inflammatory classically activated
macrophages (Figure 4). These changes are discussed in this
section.
Adipocytes, Macrophages and Type 1 Cytokine-
Associated T Cells Participate in a Proinflammatory
Positive-Feedback Loop in Obesity
In obesity adipocyte-derived inflammatory mediators such as
monocyte chemotactic protein (MCP-1), C-X-C motif chemo-
kine 12 (CXCL12), prostaglandins, leukotrienes, and other
factors are increased and promote classically activated mono-
cyte/macrophage activation, proliferation, and infiltration of
WAT (Amano et al., 2014; Nomiyama et al., 2007; Oh et al.,
2012; Weisberg et al., 2003). These cells engulf dying or dead
adipocytes, forming crown-like structures (CLS) that are char-
acterized morphologically as a ring of macrophages and other
immune cells surrounding an adipocyte (Murano et al., 2008;
Ouchi et al., 2011). The formation of CLS may be an adaptive
mechanism to scavenge cellular debris or to limit the release
of toxic lipid species when adipocytes undergo cell death via
phagocytosis. However, in addition to their phagocytic roles
in CLS, classically activated macrophages in WAT of obese
mice produce IL-1b, TNF-a, and IL-6 among other factors that
potentiate the type 1 inflammatory response (Lumeng et al.,2007; Nguyen et al., 2007; Zeyda et al., 2010). These cytokines
act directly on adipocytes and other cell types in distant
tissues such as skeletal muscle to inhibit insulin-dependent
glucose uptake (Exley et al., 2014; Gregor and Hotamisligil,
2011; Jin et al., 2013; Osborn and Olefsky, 2012). This pro-
inflammatory process is therefore associated with the develop-
ment of insulin resistance by promoting chronic low-grade type
1 inflammation.
The accumulation of macrophages in obese WAT also
appears to be regulated by CD8+ T cells (Rausch et al., 2008).
These adaptive immune cells are recruited toWAT before infiltra-
tion by pro-inflammatory macrophages in the setting of HFD
feeding (Nishimura et al., 2009). Deletion of CD8+ T cells de-
creases macrophage accumulation in WAT of obese mice and
ameliorates obesity-associated insulin resistance, and adoptive
transfer of CD8+ T cells tomice fed a HFD is sufficient to promote
macrophage infiltration of WAT and exacerbate insulin resis-
tance (Nishimura et al., 2009). In the setting of HFD feeding,
CD8+ T cells produce IFN-g that has multiple effects on immune
cells in WAT (Revelo et al., 2015). IFN-g acts on macrophages to
upregulate expression of pro-inflammatory effector cytokines
and to increase expression of Major histocompatibility complex
class II (MHCII) (Schroder et al., 2004). This promotes macro-
phage antigen presentation to CD4+ T cells and induces Th1
cell polarization and proliferation (Cho et al., 2014; Morris
et al., 2013). T-bet-dependent CD4+ Th1 cells produce TNF-a
and IFN-g to further potentiate insulin resistance in WAT (Cho
et al., 2014; Morris et al., 2013; Stolarczyk et al., 2013). Thus,
the CD8+ T cell/classically activated macrophage pathway in
WAT appears to be critical for establishing the pro-inflammatoryCell 161, March 26, 2015 ª2015 Elsevier Inc. 153
environment that influences Th1 cell responses. However, the
precise factors that spur this CD8+ T cell-dependent response
remain to be determined.
Adipocytes also appear to directly contribute to Th1 cell
responses in obesity. With increased triglyceride deposition,
adipocytes upregulate their expression of leptin, a hormone
that limits food intake, as a compensatory mechanism to guard
against overly rapid weight gain (Allison and Myers, 2014). While
this is a beneficial response to maintain energy homeostasis, in
WAT leptin acts on CD4+ T cells to induce Th1 polarization and
IFN-g expression to drive a pro-inflammatory immune response
that limits insulin sensitivity (Deng et al., 2013). In turn, IFN-g up-
regulates CIITA andMHCII expression in adipocytes (Deng et al.,
2013) and macrophages (Cho et al., 2014; Morris et al., 2013) to
promote adipocyte-mediated antigen presentation to Th1 cells.
TheseMHCII-mediated inflammatory changes in obesity are crit-
ical drivers of insulin resistance (Cho et al., 2014; Deng et al.,
2013). Therefore it appears that adipocytes, macrophages,
CD8+ T cells, and CD4+ Th1 cells participate in a pro-inflamma-
tory positive-feedback loop with deleterious consequences for
WAT inflammation and glucose metabolism.
Alternatively Activated Macrophages Acquire a
Classical Activation State in Obesity and Potentiate
Type 1 Inflammation in WAT
As discussed above, AAMacs have critical roles for regulating
metabolic homeostasis in WAT at steady state. In obesity, how-
ever, AAMacs appear to become dysregulated and acquire a
pro-inflammatory classically activated-like phenotype that con-
tributes to the development of type 1 inflammatory responses
in WAT. For example, in obesity, AAMacs decrease their expres-
sion of IL-10 and Arginase 1 and upregulate expression of
TNF-a, IL-6, and IL-1b (Han et al., 2013; Lumeng et al., 2007;
Moraes-Vieira et al., 2014). This phenotypic switch in AAMacs
appears to be driven, at least in part, by RBP4 that is upregulated
in obesity and that impairs glucose homeostasis (Graham et al.,
2006; Norseen et al., 2012). AAMacs from transgenic mice that
overexpress RBP4 exhibit upregulated expression of antigen
presentation machinery, TNF-a and IL-1b, and polarize CD4+
T cells in WAT toward a Th1 phenotype characterized by
increased expression of T-bet and IFN-g (Moraes-Vieira et al.,
2014). Interestingly, this effect was not observed in the liver, sug-
gesting a tissue-specific effect of RBP4 on antigen presenting
cells and T cell activation (Moraes-Vieira et al., 2014). In addition,
transfer of RBP4-activated bone marrow-derived dendritic cells
(DCs) (BMDCs) to lean recipient mice was sufficient to promote
Th1 cell polarization in WAT and insulin resistance compared
to unactivated BMDCs (Moraes-Vieira et al., 2014). This sug-
gests that AAMacs in WAT become dysregulated in the setting
of obesity and acquire a pro-inflammatory classical activation
state that supports Th1 cell polarization and the development
of insulin resistance.
Perspectives and Conclusions
Adipose tissues are diverse in their structure and function and
have multiple roles in the regulation of energy balance and
weight gain (Figure 1). WAT is essential for triglyceride storage
and regulation of glucose homeostasis, and white adipocytes
appear to link mammalian metabolic status to immune cell re-154 Cell 161, March 26, 2015 ª2015 Elsevier Inc.sponses. In addition, WAT contains beige adipocytes that have
been shown to be key regulators of energy expenditure and
the development of obesity. In the lean state, WAT is populated
by type 2 cytokine-associated immune cells including AAMacs,
eosinophils, ILC2s, Th2, and iNKT cells as well as anti-inflamma-
tory cells such as Tregs. These immune cells participate in a com-
plex dialog to maintain optimal immune and adipocyte function
(Figure 2). Although the precise mechanisms by which type 2 im-
mune cells in WAT regulate each other, it appears that elicitation
of these cell pathways is associated with increased insulin sensi-
tivity, optimal adipocyte mitochondrial function and in some
cases elicitation of beige adipocytes within WAT (Figure 3).
Conversely, disruption of these immunologic pathways results
in impaired adipocyte function characterized by insulin resis-
tance, oxidative stress, impaired respiratory capacity, and tri-
glyceride deposition resulting in adipocyte hypertrophy and
weight gain. Therefore, type 2 immune pathways in WAT appear
to have protective roles that support maintenance of metabolic
homeostasis and limit the development of obesity. This implies
that eliciting type 2 immune cell pathways may be a useful strat-
egy to treat or prevent obesity.
However, in the context of obesity, the immunologic milieu
of WAT undergoes a dramatic shift from a type 2 to type 1 cyto-
kine-associated inflammatory environment (Figure 4). Type 2
immune cells are decreased or dysregulated (e.g., ILC2s and
eosinophils), and in some cases acquire a pro-inflammatory
phenotype (e.g., iNKT cells and AAMacs). As type 2 immune cells
tend to be associated with protection against obesity, these
alterations in type 2 cytokine-associated immunologic pathways
may contribute to the development of obesity and subsequent
type 1 inflammatory responses. In addition, in obesity there is
recruitment of various granulocytes, monocytes, and lympho-
cytes to WAT. These cell types produce cytokines such as
TNF-a, IFN-g, and IL-1b among others that potentiate type 1 im-
mune responses and enhance antigen presentation to CD4+
T cells, polarizing these cells toward a Th1 cell phenotype. In
turn, Th1 cells produce additional TNF-a and IFN-g, establishing
a positive-feedback loop resulting in chronic low-grade type 1
inflammation and dysregulated glucose homeostasis. The
precipitating factors that initiate type 1 immune responses in
WAT are not well understood but may be related to adipocyte
cell death (Spalding et al., 2008), hypoxia (Lee et al., 2014b;
Sun et al., 2011), the generation of toxic lipid species (Muoio
and Newgard, 2006), direct effects of dietary lipids or carbohy-
drates (Calder, 2002), and translocation of commensal bacteria
to WAT (Amar et al., 2011; Cani et al., 2007) among other
factors. The apparent multifactorial nature of the type 1 immune
response inWAT suggests that targeting downstream inflamma-
tory mediators such as IFN-g, TNF-a, or IL-1bmight have bene-
ficial therapeutic effects in obesity-associated insulin resistance.
Finally, emerging studies have revealed complex immuno-
modulatory cross-talk between the type 1 and type 2 immune
systems, where type 2 inflammation impairs type 1 responses
and vice versa (Osborne et al., 2014; Reese et al., 2014; Stelekati
and Wherry, 2012). Given the complex, dramatic shift in the
immunologic landscape within obese WAT from a type 2 to
type 1 cytokine-associated response, targeting a single immu-
nologic factor may not be sufficient to treat obesity and restore
a normal immunologic profile in WAT. Clinical trials employing
biologic agents that inhibit IL-1 (anakinra, canakinumab) or
TNF-a (infliximab) in patients with type 2 diabetes or metabolic
syndrome have been shown to produce moderate or no im-
provements in glucose metabolism, as assessed by glycated
hemoglobin levels or indices of insulin resistance (Larsen et al.,
2007; Ridker et al., 2012; Wascher et al., 2011). However the ef-
fects of these therapies on body weight or adiposity is not clear.
Further research on immunomodulatory biologic therapy to treat
obesity should be considered. In addition, the effectiveness of
‘‘two-factor’’ immunomodulatory therapies (e.g., neutralizing
TNF-a antibody plus recombinant IL-33) should be explored as
potential anti-obesity regimens. Targeting the immune system
with biologics could represent a new strategy to limit food intake
and/or increase energy expenditure to treat or prevent obesity
and related metabolic diseases such as type 2 diabetes. In addi-
tion, understanding how current and future treatments for
obesity (e.g., diet, exercise, drugs, and surgery) influence the
immune system will be important for understanding their mech-
anisms of action and the potential side effects of treatment.
Therefore, a deeper understanding of how the immune and
metabolic systems interact to support metabolic homeostasis
will be critical for understanding the biology of obesity and for
the development of novel treatment and prevention strategies
against this disease.
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